{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continue+PD-1%2FPD-L1+Inhibitors+treatment", "query": { "intervention": "Continue PD-1/PD-L1 Inhibitors treatment" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 12, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continue+PD-1%2FPD-L1+Inhibitors+treatment&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-05T05:22:28.246Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02579811", "title": "Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Renal Cell Cancer" ], "interventions": [ { "name": "Axitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2015-12-30", "completion_date": "2023-06-20", "has_results": true, "last_update_posted_date": "2023-06-29", "last_synced_at": "2026-10-05T05:22:28.246Z", "location_count": 4, "location_summary": "Duarte, California • Cleveland, Ohio • Columbus, Ohio + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02579811" }, { "nct_id": "NCT05576077", "title": "A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Colorectal Cancer", "Uveal Melanoma", "Cutaneous Melanoma", "Non-Small Cell Lung Cancer", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "TBio-4101", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Turnstone Biologics, Corp.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 31, "start_date": "2023-01-17", "completion_date": "2025-02-24", "has_results": false, "last_update_posted_date": "2025-03-10", "last_synced_at": "2026-10-05T05:22:28.246Z", "location_count": 11, "location_summary": "Irvine, California • Hollywood, Florida • Miami, Florida + 8 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05576077" }, { "nct_id": "NCT04674683", "title": "Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Unresectable or Metastatic Melanoma", "Progressive Brain Metastasis" ], "interventions": [ { "name": "HBI-8000 in combination with nivolumab", "type": "DRUG" }, { "name": "Placebo in combination with nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HUYABIO International, LLC.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 450, "start_date": "2021-08-12", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-09-24", "last_synced_at": "2026-10-05T05:22:28.246Z", "location_count": 31, "location_summary": "Bakersfield, California • La Jolla, California • Pasadena, California + 28 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Redlands", "state": "California" }, { "city": "Riverside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04674683" }, { "nct_id": "NCT03220854", "title": "SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Stereotactic radiotherapy", "type": "RADIATION" }, { "name": "Biological: humanized anti-PD-1 monoclonal antibody", "type": "OTHER" }, { "name": "Biological: humanized anti-PD-L1 monoclonal antibody", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "OTHER" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2017-10-10", "completion_date": "2021-09-22", "has_results": true, "last_update_posted_date": "2022-01-10", "last_synced_at": "2026-10-05T05:22:28.246Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03220854" }, { "nct_id": "NCT05013450", "title": "Dupilumab_Metastatic NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "PD-1/PD-L1 blockade", "type": "DRUG" }, { "name": "Anakinra", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Thomas Marron", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2021-09-10", "completion_date": "2030-09-18", "has_results": false, "last_update_posted_date": "2026-08-31", "last_synced_at": "2026-10-05T05:22:28.246Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05013450" }, { "nct_id": "NCT02973789", "title": "Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Nonsmall Cell Lung Cancer", "NSCLC" ], "interventions": [ { "name": "NovoTTF-200T", "type": "DEVICE" }, { "name": "Immune checkpoint inhibitors or docetaxel", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "DRUG" ], "sponsor": "NovoCure GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 291, "start_date": "2016-12", "completion_date": "2024-10-09", "has_results": true, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-10-05T05:22:28.246Z", "location_count": 73, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 59 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02973789" }, { "nct_id": "NCT03340766", "title": "Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)" ], "interventions": [ { "name": "Blinatumomab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 31, "start_date": "2018-03-16", "completion_date": "2023-08-14", "has_results": true, "last_update_posted_date": "2024-10-17", "last_synced_at": "2026-10-05T05:22:28.246Z", "location_count": 3, "location_summary": "La Jolla, California • Charleston, South Carolina • Greenville, South Carolina", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Charleston", "state": "South Carolina" }, { "city": "Greenville", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03340766" }, { "nct_id": "NCT05098210", "title": "Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Locally Advanced Cutaneous Melanoma", "Locally Advanced Mucosal Melanoma", "Metastatic Acral Melanoma", "Metastatic Conjunctival Melanoma", "Metastatic Cutaneous Melanoma", "Metastatic HER2-Negative Breast Carcinoma", "Metastatic Hormone Receptor-Positive Breast Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Mucosal Melanoma", "Pathologic Stage IIIC Cutaneous Melanoma AJCC v8", "Pathologic Stage IIID Cutaneous Melanoma AJCC v8", "Recurrent Cutaneous Melanoma", "Recurrent HER2-Negative Breast Carcinoma", "Recurrent Hormone Receptor-Positive Breast Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Recurrent Mucosal Melanoma", "Stage III Lung Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Unresectable Acral Melanoma", "Unresectable Cutaneous Melanoma", "Unresectable Lung Non-Small Cell Carcinoma", "Unresectable Mucosal Melanoma" ], "interventions": [ { "name": "Neoantigen Peptide Vaccine", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Poly ICLC", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2022-06-09", "completion_date": "2028-11-01", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-05T05:22:28.246Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05098210" }, { "nct_id": "NCT03616834", "title": "Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Tomivosertib (eFT-508)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Effector Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2018-07-25", "completion_date": "2021-06-30", "has_results": false, "last_update_posted_date": "2023-03-22", "last_synced_at": "2026-10-05T05:22:28.246Z", "location_count": 19, "location_summary": "Tucson, Arizona • Long Beach, California • Los Angeles, California + 15 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03616834" }, { "nct_id": "NCT04157985", "title": "Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Solid Tumors", "NSCLC", "Bladder Cancer", "HNSCC", "Renal Cancer", "Melanoma", "Anal Cancer", "Colorectal Cancer", "Cholangiocarcinoma", "Gastric Cancer", "Hepatocellular Carcinoma", "Merkel Cell Carcinoma", "Cervical Cancer" ], "interventions": [ { "name": "Continue PD-1/PD-L1 Inhibitors treatment", "type": "DRUG" }, { "name": "Discontinue PD-1/PD-L1-1 inhibitor", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Dan Zandberg", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 161, "start_date": "2019-11-15", "completion_date": "2025-11-07", "has_results": false, "last_update_posted_date": "2025-12-11", "last_synced_at": "2026-10-05T05:22:28.246Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04157985" } ] }